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IMPORTANCE Postmenopausal status coincideswith increased risks for chronic conditions such
as heart disease, osteoporosis, cognitive impairment, or some types of cancers. Previously,
hormone therapywas used for the primary prevention of these chronic conditions.
OBJECTIVE To update evidence for the US Preventive Services Task Force on the benefits and
harms of hormone therapy in reducing risks for chronic conditions.
DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries from June 1, 2011,
through August 1, 2016. Surveillance for new evidence in targeted publications was
conducted through July 1, 2017.
STUDY SELECTION English-language randomized clinical trials reporting health outcomes.
DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study
quality; meta-analyses when at least 3 similar studies were available.
MAIN OUTCOMES ANDMEASURES Beneficial or harmful changes in risks for various
chronic conditions.
RESULTS Eighteen trials (n = 40058; range, 142-16608;mean age, 53-79 years) were included.
Women using estrogen-only therapy comparedwith placebo had significantly lower risks, per
10000person-years, for diabetes (−19 cases [95%CI, −34 to −3]) and fractures (−53 cases
[95%CI, −69 to −39]). Riskswere statistically significantly increased, per 10000person-years,
for gallbladder disease (30more cases [95%CI, 16 to 48]), stroke (11more cases [95%CI,
2 to 23]), venous thromboembolism (11more cases [95%CI, 3 to 22]), and urinary incontinence
(1261more cases [95%CI, 880 to 1689]).Women using estrogen plus progestin comparedwith
placebo experienced significantly lower risks, per 10000person-years, for colorectal cancer
(−6 cases [95%CI, −9 to −1]), diabetes (−14 cases [95%CI, −24 to −3), and fractures (−44 cases
[95%CI, −71 to −13). Risks, per 10000person-years, were significantly increased for invasive
breast cancer (9more cases [95%CI, 1 to 19]), probable dementia (22more cases [95%CI,
4 to 53]), gallbladder disease (21more cases [95%CI, 10 to 34]), stroke (9more cases [95%CI,
2 to 19]), urinary incontinence (876more cases [95%CI, 606 to 1168]), and venous
thromboembolism (21more cases [95%CI, 12 to 33]).
CONCLUSIONS AND RELEVANCE Hormone therapy for the primary prevention of chronic
conditions in menopausal women is associated with some beneficial effects but also with
a substantial increase of risks for harms. The available evidence regarding benefits and harms
of early initiation of hormone therapy is inconclusive.
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T heonsetofmenopausecoincideswithan increased risk forcommon,preventablediseases suchas cardiovascular dis-ease, osteoporosis (and subsequent fractures), cognitive
impairment, and some types of cancers. Before publication of the
Women’s Health Initiative (WHI) in 2002,1 hormone therapy was
commonlyprescribed forprimarypreventionof these conditions in
womenwithandwithoutmenopausal symptoms.Hormonetherapy
has various forms, doses, and regimens of estrogen with or with-
outprogestin.2Womenwhohavenothadhysterectomiesuseacom-
bination therapy of estrogen plus progestin to prevent endome-
trial proliferation and endometrial cancer; women who have had
hysterectomies use only estrogen.
Natural menopause occurs at a median age of 51.3 years, and
questions persist whether the initiation of hormone therapy at a
younger age than in the WHI trials (mean age, 63 years) could re-
duce the riskof cardiovasculardisease,3,4dementia,5 andmortality6
(a concept often referred to as the timing hypothesis).
This review updates evidence on benefits and harms of hor-
mone therapy for the primary prevention of chronic conditions to
informa recommendationby theUSPreventiveServicesTaskForce
(USPSTF). In2013, theUSPSTFrecommendedagainst theuseofhor-
mone therapy for the primary prevention of chronic conditions
(grade D recommendation).
Methods
Scope of Review
This review updates a previous review for the USPSTF on this
topic.7 Detailedmethods are available in the full evidence report at
https://www.uspreventiveservicestaskforce.org/Page/Document
/final-evidence-review/menopausal-hormone-therapy-preventive
-medication1. Figure 1 presents the analytic framework and key
questions (KQs) that guided the review.
Data Sources and Searches
MEDLINE (via PubMed), the Cochrane Library, EMBASE, and Inter-
national Pharmaceutical Abstracts were searched for English-
languagearticlespublishedfromJune1,2011, throughAugust 1,2016.
Targeted searches were conducted for unpublished literature
(ClinicalTrials.gov, the Health Services Research Projects in Process,
the World Health Organization International Clinical Trials Registry
Platform, NIHReporter, andDrugs@FDA.gov). This search included
relevant citations from the previous review,7 reference lists of other
pertinent reviewarticles, and literature suggestedbypeer reviewers
or public comment respondents. The eMethods in the Supplement
present detailed search strategies for electronic databases.
Between August 2016 and July 2017, ongoing surveillance
througharticle alerts and targetedsearchesof journalswithhigh im-
pact factors helped ensure inclusion of major studies affecting the
conclusions or understanding of the evidence and the related
USPSTF recommendation.
Study Selection
Two investigators independently reviewedtitles, abstracts, and full-
textarticles todetermineeligibilityusingprespecifiedcriteria foreach
KQ (eTable 1 in theSupplement). Conflictswere resolvedbydiscus-
sion and consensus.
The review included studies of generally healthy perimeno-
pausal and postmenopausal women who were eligible for hor-
mone therapy. Women with and without menopausal symptoms
were included if the focus of the analysis was on either the primary
prevention of chronic conditions or harms of hormone therapy. In
some cases the review included populations for which use of hor-
mone therapy was intended for secondary prevention if there was
an additional focus of the analysis on primary prevention or harms.
The reviewexamineduseof systemic therapy (ie, pill, patch, or
injection) with estrogen-only formulations or combination prepa-
rations of estrogen plus progestin of 1 year ormore for the primary
preventionof chronic conditions.Medicationshad tohavebeenap-
provedbytheUSFoodandDrugAdministration for thispurposeand
had to be available for use in the United States (Table 1).
For all KQs, the review included trials enrollingwomen frompri-
mary care settingsbutnot inpatient or institutional settings suchas
nursing homes or similar facilities.
With respect to geography, the review included studies con-
ducted in theUnitedStatesor in countriesdesignatedby theUnited
Nations Development Programme as having a very high Human
Development Index.11
Data Extraction andQuality Assessment
Foreach includedstudy, 1 investigator abstracted informationabout
design,population, intervention, comparator, outcome, timing, and
setting. A second investigator reviewed for completeness and ac-
curacy. Differences were resolved by consensus or adjudication by
a third senior investigator. Two investigators independently as-
sessed thequality of each study as good, fair, or poor usingUSPSTF
predefined criteria.12 Individual study quality ratings are provided
in eTable 2 in the Supplement.
Data Synthesis and Analysis
The review includes qualitative synthesis for each KQ. Assessing the
numberoftrialsavailableandtheirclinicalandmethodologicalhetero-
geneity(followingestablishedguidance13)helpeddeterminewhether
meta-analyses were appropriate. When at least 3 similar trials were
available,quantitativesynthesisofstudieswithrandom-effectsmodels
was conducted, using the inverse-variance–weighted method
(DerSimonianandLaird). Forall quantitativesyntheses, theχ2 statis-
tic and the I2 statistic (the proportion of variation in study estimates
attributable to heterogeneity rather than chance) were calculated
to assess statistical heterogeneity in effects between studies.14
Theoutcomemeasure for all quantitativeanalyseswas the rela-
tive risk of abeneficial or harmful change in risks (eg, increaseor re-
duction of cardiovascular events). Absent meta-analytic esti-
mates, relative risks of outcomes of interest were based primarily
onarecentpublicationsummarizingresultsof theWHItrials.15There-
fore, effect estimates might differ slightly from hazard ratios re-
ported in earlier WHI publications.
All quantitative analyseswere basedonComprehensiveMeta-
Analysis Version 3 (Biostat Inc). Statistical significance was as-
sumedwhen95%CIs of pooled results did not cross the null (ie, 1).
All testing was 2-sided.
Thestrengthofevidencewasratedforeachmajoroutcomeusing
the domains set out in guidance from the Agency for Healthcare
Research and Quality.16 Two reviewers assessed each strength-of-
evidence domain for each key outcome and developed the overall
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strength-of-evidencegrades.Strength-of-evidencegradesreflect the
confidencethatthereviewershavethatvariousestimatesofeffectare
close to true effectswith respect to theKQs in a systematic review.
Results
The searches identified 2241 citations (Figure 2). Overall, 68 articles
from the previous review7 and this update represented a total of 18
good-or fair-quality trials. Includedarticlesprovideddataon40058
perimenopausal and postmenopausal women comparing the ef-
fectsofestrogen,eitheraloneor incombinationwithprogestin,with
placebo for the primary prevention of chronic conditions. Of the 18
included trials, 13were conducted in the United States. The remain-
ing trials camefromAustralia,Canada,Estonia,NewZealand,andthe
UnitedKingdom. Theduration of follow-up in the trials averaged 3.5
years.Themeanageofwomenparticipating in trials rangedfrom5317
to7918years.Themajorityofparticipantswerewhite;proportionsof
women of other races/ethnicities ranged from 1%19 to 41%.20
Table 2 summarizes the main characteristics and quality rat-
ings of eligible trials. Of these trials, 5 were rated as of good quality
and 13 as of fair quality. Three trials (described in Table 2)met eligi-
bility criteria24,30,35; however, they did not stratify results by regi-
men (ie, estrogen only or estrogen plus progestin), so their find-
ings could not be used for our analyses.
TheWHI trials were the only studies powered to assess the ef-
fectiveness of hormone therapy for the primary prevention of
various chronic conditions.15 They enrolled generally healthy post-
menopausalwomen aged 50 to 79 years and compared oral conju-
gatedequineestrogen (0.625mg/d),withorwithoutmedroxypro-
gesterone (2.5mg/d), with placebo. TheWHI trials had the longest
follow-upamong includedtrials (medianof7.2years for theestrogen-
only trial; 5.6 years for the estrogen plus progestin trial). Outcome-
specific evidence from the WHI and other trials are available in
eTables 3 through 18 in the Supplement.
Benefits of Menopausal Hormone Therapy
Key Question 1. What are the benefits of menopausal hormone
therapywhenusedfor theprimarypreventionofchronicconditions?
Estrogen Only
For women using estrogen only, the risks for osteoporotic frac-
tures and diabetes, and the long-term risk for breast cancer, were
statistically significantly reduced. Long-term observational
follow-up studies of theWHI showed that, except for a reduced risk
of invasive breast cancer, beneficial effects did not persist after
stopping hormone therapy. Outcomes with no statistically signifi-
cant reductions in risk includedcolorectal cancer, lungcancer, coro-
nary heart disease, probable dementia, quality of life, and all-cause
mortality. Some of these nonsignificant outcomes, however, had
wideconfidence intervalsencompassingbothclinically relevantben-
efits andharms, leading to inconclusive results.Table3presents the
estimated increases or reductions of events for various outcomes
per 10000 person-years for women who received estrogen-only
therapy comparedwith thosewho receivedplacebo. Estimates are
based onmeta-analyses of included trials or, ifmeta-analyseswere
not feasible, on results from the largest and most reliable trial
(usually theWHI).Figure 3depicts the corresponding absolute risk
differences with 95% CIs. Table 4 summarizes the underlying
strength of evidence.
Figure 1. Analytic Framework and Key Questions
Key questions
1 What are the benefits of menopausal hormone therapy when used for the primary prevention
of chronic conditions?
What are the harms of menopausal hormone therapy when used for the primary prevention
of chronic conditions?
2
Do the benefits and harms of menopausal hormone therapy differ by subgroup (race or ethnicity;
women with premature menopause; women with surgical menopause; age during hormone
therapy use; duration of use; type, dose, and mode of delivery of hormone therapy; and comorbid
condition) or by timing of intervention (initiation of hormone therapy during perimenopause
vs postmenopause)?
3
Health outcomes
Improved health outcomes
Reduction in mortality
Perimenopausal and
postmenopausal womena
Harms of
treatment
2
3
Intermediate outcomes
Hormone therapy
Estrogen
Estrogen plus progestin
1 3
Evidence reviews for the
US Preventive Services Task Force
(USPSTF) use an analytic framework
to visually display the key questions
(KQs) that the reviewwill address to
allow the USPSTF to evaluate the
effectiveness and safety of a
preventive service. The questions
are depicted by linkages that relate
interventions and outcomes.
A dashed line indicates a relationship
between an intermediate outcome
and a health outcome that is
presumed to describe the natural
progression of the disease. Further
details are available in the USPSTF
procedure manual.8
a Definitions of perimenopausal and
postmenopausal women are based
on STRAW+ 10 criteria.9
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TheWHI (n = 10 739)15 reported statistically significant reduc-
tions in risk for osteoporotic fractures amongwomen taking estro-
gen-only therapy comparedwithwomen taking placebo (−53 frac-
tures per 10 000 patient-years [95% CI, −69 to −39]). Likewise,
based on WHI data (n = 9917), the incidence of diabetes was sig-
nificantly reduced inwomentakingestrogen-only therapy(−19cases
per 10000 patient-years [95% CI, −34 to −3]).15,37
Five randomized clinical trials15,21-23,29,36,48,49,61,77,79 with data
onmore than 13000womenreportedbreast cancer incidence.Trial
resultswerenotpooled,primarilybecauseofheterogeneity in study
duration and outcome measures. In the WHI (n = 10 739), estro-
genaloneproducedanonsignificantdecrease in invasivebreast can-
cer risk comparedwith placebo during the 7.2-year (median) inter-
vention phase (−7 cases per 10 000 patient-years [95% CI, −14
+0.4]).15,48Between-groupdifferencesbecamestatistically signifi-
cant during cumulative (trial and postintervention phase; median,
13 years) follow-up (hazard ratio [HR], 0.79 [95%CI, 0.65-0.97]).15
Estrogen plus Progestin
Women taking combination therapy experienced statistically sig-
nificant reductions in risk for colorectal cancer, osteoporotic frac-
tures, and diabetes compared with women in the placebo groups
(Figure 3). Except for a lower risk of colorectal cancer, beneficial as-
sociations did not persist after stopping hormone therapy. No sta-
tistically significantdifferences for cervical cancer, endometrial can-
cer, lungcancer,ovariancancer,qualityof life, andall-causemortality
were found. Someof thesenonsignificant outcomes, however, had
wideconfidence intervalsencompassingbothclinically relevantben-
efitsandharms, leadingto inconclusive results (Table3andFigure3).
Table 5 summarizes the underlying strength of evidence.
Fourtrials (theWHI[n = 16608],1,15,54,61,67 theEstrogenMemory
Study [EMS; n = 142],18 the Heart and Estrogen Replacement Study
[HERS; n = 2763],80 and the Women’s International Study of Long
DurationEstrogenAfterMenopause[WISDOM;n = 4385]19)withdata
onmore than 20000women reported on the incidence of colorec-
talcancer.DuringtheWHI interventionphase,womenreceivingcom-
binationtherapyexperiencedastatisticallysignificantreduction inrisk
for colorectal cancer (−6casesper 10000patient-years [95%CI, −9
to−1]).TheHERStrial reportedanumericdecrease in the riskofcolo-
rectal cancer with use of estrogen plus progestin during 4.1 years of
follow-up(HR,0.69[95%CI,0.32-1.49]);EMS(n = 142)andWISDOM
(n = 4385)hadtoosmall samplesizesandwereof tooshortduration
to have adequate power to detect differences in rates of colorectal
cancer (<2 years; zero events in EMSand4events inWISDOM).
Estrogen plus progestin therapy protected against incident dia-
betesamongwomeninHERS(n = 2029)27andtheWHI(n = 15874).60
In theWHI, the largerof the2 trials, newdiabetesdiagnosesweresig-
nificantly reduced in women receiving hormone therapy compared
with women receiving placebo (−14 cases per 10000 patient-years
[95%CI, −24 to −3]).15,60
Fivetrials(n = 20499)reportedonfractures:EMS(n = 142),18the
EstonianPostmenopausalHormoneTherapyTrial (EPHT; n = 777),20
theEstrogenReplacementandAtherosclerosisStudy(ERA;n = 209),22
HERS (n = 2763),80 and the WHI (n = 16608).1,15,52,67 In our
Table 1. Systemic Hormone Therapies Approved by the US Food and Drug Administration2,10
Hormone Therapy Category
and Generic Name
Brand
Name Product Type Dosagea
Estrogen-Only Formulations
Estradiolb Alora Patch 0.025 mg to 0.1 mg, worn for 24 h twice weekly
Climara Patch 0.025 mg to 0.1 mg, worn for 24 h once weekly
Estrace Pill 0.5 mg/d to 2 mg/d
Estraderm Patch 0.05 mg to 0.1 mg, continuously or cyclicallyc
Menostar Patch 0.014 mg, worn for 24 h once weekly
Minivelle Patch 0.025 mg/24 h to 0.1 mg/24 h, worn for 24 h twice weekly
Vivelle Patch 0.0375 mg to 0.1 mg daily
Vivelle-Dot Patch 0.025 mg to 0.1 mg, worn for 24 h twice weekly
Estradiol acetateb Femtrace Pill 0.45 mg/d to 1.8 mg/d, daily
Esterifield estrogenb Menest Pill 0.3 mg/d to 1.25 mg/d, cyclicallyc
Estropipated Ogen Pill 0.75 mg/d to 3 mg/d
Conjugated estrogense Premarin Pill, injection 0.3 mg/d cyclically, single 25-mg injectionc
Synthetic conjugated
estrogensf
Enjuvia Pill 0.3 mg/d
Combination Estrogen + Progestin Formulations
Estradiol +
drospirenoneb,g
Angeliq Pill Drospirenone (0.25 mg/d to 0.5 mg/d) + estradiol
(0.5 mg/d to 1 mg/d)
Estradiol +
norethindrone
acetateb,f
Activella Pill Estradiol (0.5 mg/d to 1 mg/d) + norethindrone
(0.1 mg/d)
Combipatch Patch Estradiol (0.05 mg) + norethindrone (0.14 mg
to 0.25 mg), worn for 24 h once weekly
Estradiol +
norgestimateb,g
Prefest Pill Repeat estradiol (1 mg/d) for 3 d, followed by estradiol
(1 mg/d) + norgestimate (0.09 mg/d) for 3 d
Estradiol +
levonorgestrelb,g
Climara
Pro
Patch Estradiol (0.045 mg) + levonorgestrel (0.015 mg),
worn for 24 h once weekly
Conjugated estrogen + MPAg Prempro Pill Conjugated estrogen (0.625 mg/d) + MPA (5 mg/d)
Ethinyl estradiol +
norethindrone acetateb,f
Femhrt Pill Ethinyl estradiol (0.0025 mg/d) + norethindrone acetate
(0.5 mg/d)
Abbreviation: MPA,
medroxyprogesterone acetate.
a Dosages are based on the package
inserts for the brand-name
formulations.
b Estradiol can be from natural
sources or prepared synthetically.
c Cyclically indicates “within a cycle,”
eg, repeat 3 weeks of treatment and
1 week off.
dNatural estrogenic substance
prepared from purified crystalline
estrone.
e Conjugated estrogens, such as
conjugated equine estrogens, are
derived wholly or partially from the
urine of pregnant mares or from
synthetic estrone and equilin.
f Synthetic conjugated estrogens are
prepared using plant sources, such
yams and soy, and use only
synthetic resources.
g Synthetic progestin.
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random-effectsmeta-analysis(eFigure1 intheSupplement),combina-
tiontherapywasassociatedwithastatisticallysignificantriskreduction
forfractures(−44casesper10000patient-years[95%CI,−71to−13]).
Harms ofMenopausal Hormone Therapy
KeyQuestion2.Whataretheharmsofmenopausalhormonetherapy
whenused for the primary prevention of chronic conditions?
Estrogen Only
Women receiving estrogen-only therapy had statistically signifi-
cant increases in risk for gallbladder disease, stroke, urinary incon-
tinence,andvenousthromboembolism(Table3andFigure3;Table4
summarizes the strength of evidence). Increased risks did not per-
sist after stopping hormone therapy.
The Postmenopausal Estrogen/Progestin Interventions Trial
(PEPI;n = 349)29andtheWHI (n = 8376)40 reported increasedrisks
for gallbladder disease in women receiving estrogen-only therapy.
In theWHI, the increased risk was statistically significant (30more
cases per 10000 patient-years [95% CI, 16 to 48]).
Of3 trialsassessing theriskof stroke (Estrogen in thePrevention
ofAtherosclerosisTrial [EPAT;n = 222],21ERA[n = 205],andtheWHI
[n = 10739]15,48),onlytheWHIprovidedstatisticallysignificantresults.
Estrogen-only therapy led to a statistically significant increase in risk
for stroke (11morecasesper 10000patient-years [95%CI,2 to23]).
Two trials (the Ultra-Low-Dose Transdermal Estrogen Assess-
ment [ULTRA; n = 239]33 and the WHI [n = 3073]42) with data on
more than 3200 continentwomen found higher risks of urinary in-
continence (self-reported) in thetreatmentgroups forall timepoints
(1261more casesper 10000patient-years [95%CI, 880 to 1689]).
Basedon theWHI (n = 10 739) results,15womenrandomized to
estrogen-only therapy had a statistically significant increase in risk
of venous thromboembolism comparedwith those randomized to
placebo (11more casesper 10000patient-years [95%CI, 3 to 22]).
To balance benefits and harms, the WHI used a global index
basedonbeneficial andharmful events. For estrogen-only therapy,
the global index did not showa statistically significant difference in
overall beneficial or harmful events (HR, 1.03 [95% CI, 0.93-1.13]).
Estrogen plus Progestin
Womenreceivingcombinationtherapyhadstatistically significant in-
creases in risk for invasivebreastcancer,probabledementia,gallblad-
der disease, stroke, urinary incontinence, and venous thromboem-
bolismcomparedwithwomenreceivingplacebo(Table3andFigure3;
Table 5 summarizes the strength of evidence).
Figure 2. Summary of Evidence Search and Selection
6765 Abstracts of potentially relevant articles
identified through MEDLINE, Cochrane,
and other sources (2241 newly identified)a
46 Articles (15 trials) included for KQ2 20 Articles (3 trials) included for KQ337 Articles (14 trials) included for KQ1
5809 Abstracts and background articles
excluded (1989 newly identified)
888 Articles excluded
235 Newly identified articles excluded
8 Non-English publication
92 Ineligible publication type
14 Ineligible population
22 Ineligible intervention
4 Ineligible indication
13 Ineligible duration
43 Ineligible design
2 Superseded by more recent review
6 Ineligible sample size
14 Irrelevant outcomes
5 Intermediate outcomes
5 Ineligible setting
2 Review does not answer KQs
5 Poor quality
653 Data not available
956 Full-text articles reviewed for relevance
to key questions (252 newly identified)
68 Articles (18 trials) included in systematic
review (17 articles [9 trials] newly identified)
Six articles from theWomen’s Health Initiative reported results of unblinded,
long-term postintervention follow-up. These articles were used in addressing
key questions (KQs) 1 and 2 only.
a Searches were conducted of MEDLINE, the Cochrane Library, EMBASE,
International Pharmaceutical Abstracts, ClinicalTrials.gov, Drugs@FDA.gov,
the Health Services Research Projects in Process, NIH Reporter, and theWorld
Health Organization International Clinical Trials Registry Platform.
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Table 2. Characteristics of Randomized Clinical Trials of Use of Hormone Therapy
Trial Name, Source Country and Participant Information Intervention and Durationa
Quality
Ratingb
Estrogen Memory Study (EMS)
Tierney et al, 200918
Canada
Ages 61-87 y
Last menstrual cycle >12 mo before screening
Fluent in English and could read normal print and hear
normal speech
17β-estradiol (1 mg/d for 4 d) then 17β-estradiol
(1 mg) + norethindrone (0.35 mg/d) for 3 d,
repeated every week (n = 70)
Placebo (n = 72)
Duration, 2 y
Fair
Estrogen in the Prevention of
Atherosclerosis (EPAT)
Hodis et al, 201121
United States
Ages 46-80 y
Postmenopausal women with low-density lipoprotein
cholesterol level ≥130 mg/dL
Micronized 17β-estradiol (1 mg/d) (n = 111)
Placebo (n = 111)
Duration, 2 y
Fair
Estonian Postmenopausal
Hormone Therapy Trial (EPHT)
Veerus et al, 200320
Estonia
Ages 50–64 y
An elapsed 12 mo or more since the last period
at the randomization stage
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 404)
Placebo (n = 373)
Mean duration, 3.4 y
Fair
Effects of Estrogen Replacement
on the Progression of
Coronary-Artery Atherosclerosis
(ERA)
Herrington et al, 200022
United States
Ages 41-79 y
Postmenopausal women not currently receiving estrogen
replacement therapy and with >1 epicardial coronary
stenosis of ≥30% of the luminal diameter
CEE (0.625 mg/d) (n = 100)
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 104)
Placebo (n = 105)
Duration, 3 y
Fair
Estrogen in the Prevention of
Reinfarction Trial (ESPRIT)
Cherry et al, 200223
United Kingdom
Ages 50–69 y
Admitted to coronary care units or general medical wards
in participating hospitals
Met diagnostic criteria for initial myocardial infarction
Discharged from hospital within 31 d of admission
Estradiol valerate (2 mg/d) (n = 513)
Placebo (n = 504)
Duration, 2 y
Fair
Greenspan et al, 200524 United States
Ages 65-90 y
Community-dwelling women
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 187)
Placebo (n = 186)
Duration, 3 y
Good
Heart and Estrogen/Progestin
Replacement Study (HERS)
Grady et al, 199825
Hulley et al, 199826
Kanaya et al, 200327
Steinauer et al, 200528
United States
Ages ≤80 y (mean, 66.7)
Intact uterus
Postmenopausal
Established coronary artery disease
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 1380)
Placebo (n = 1383)
Mean duration, 4.1 y
Good
Kronos Early Estrogen
Prevention Study–Cognitive and
Affective Study (KEEPS-Cog)
Gleason et al, 201517
United States
Ages 42–58 y
Intact uterus
Recently postmenopausal
At risk for cardiovascular disease
CEE (0.45 mg/d) + MP (200 mg/d, 12 d/mo)
(n = 220)
Transdermal estradiol (50 μg/d) + MP (200 mg/d,
12 d/mo) (n = 211)
Placebo (n = 262)
Duration, 4 y
Fair
Postmenopausal Estrogen and
Progestin Interventions Trial
(PEPI)
PEPI, 199529
United States
Ages 45–64 y
With or without a uterus
Naturally or surgically menopausal
CEE (0.625 mg/d) (n = 175)
CEE (0.625 mg/d) + MPA (10 mg/d, 12 d/mo)
(n = 174)
CEE (0.625 mg/d) + MP (200 mg/d, 12 d/mo)
(n = 178)
Placebo (n = 174)
Duration, 3 y
Fair
STOP-IT
Gallagher et al, 200130
United States
Ages 65–77 y
Femoral neck density within normal range for age
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 121)
CEE (0.625 mg/d) + MPA (2.5 mg/d) + calcitriol
(0.25 μg twice daily) (n = 122)
Calcitriol (0.25 μg twice daily) (n = 123)
Placebo (n = 123)
Duration, 3 y
Fair
Ultra-Low-Dose Transdermal
Estrogen Assessment (ULTRA)
Ettinger et al, 200431
Johnson et al, 200532
Waetjen et al, 200533
Yaffe et al, 200634
United States
Ages 60–80 y
Intact uterus
At least 5 y past menopause
Bone mineral density normal for age
Unopposed transdermal estradiol (0.014 mg/d)
(n = 208)
Placebo (n = 209)
Duration, 2 y
Good
Women’s Angiographic Vitamin
and Estrogen Trial (WAVE)
Waters et al, 200235
United States, Canada
Postmenopausal
Mean age of 65 y
Coronary angiogram performed within 4 mo
of study entry
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 210)
Placebo (n = 213)
Mean duration, 2.8 y
Fair
Women’s Health Initiative (WHI)
Estrogen Trial
Anderson et al, 200436
Bonds et al, 200637
Brunner et al, 200538
Chlebowski et al, 201039
Cirillo et al, 200540
Curb et al, 200641
Hendrix et al, 200542
Hendrix et al, 200643
Hsia et al, 200644
Manson et al, 201315
Ritenbaugh et al, 200845
Rossouw et al, 200746
United States
Postmenopausal
Ages 50–79 y
Prior hysterectomy
3-mo washout required for women using hormone
therapy at baseline
CEE (0.625 mg/d) (n = 5310)
Placebo (n = 5429)
Median duration, 7.2 y
Fair
(continued)
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Six trials (the WHI [n = 16 608],1,15,47,53,61,66,67,79 HERS
[n = 2763],80PEPI [n = 700],29EPHT[n = 777],20ERA[n = 209],22
and WISDOM [n = 4385]19) reported on breast cancer incidence
basedondata frommore than25000women.Trial resultswerenot
Table 2. Characteristics of Randomized Clinical Trials of Use of Hormone Therapy (continued)
Trial Name, Source Country and Participant Information Intervention and Durationa
Quality
Ratingb
WHI Estrogen Trial
postintervention and
postintervention extension
phases
Chlebowski et al, 201047
LaCroix et al, 201148
Manson et al, 201315
9666 participants from WHI (90%) had any
postintervention follow up and 7645 (71%) consented
to participate in the extension phase
CEE (0.625 mg/d) (n = 5310)
Placebo (n = 5429)
Mean duration, 6.6 y
Fair
WHI Estrogen + Progestin Trial
Anderson et al, 201249
Anderson et al, 200350
Canonico et al, 201451
Cauley et al, 200352
Chlebowski et al, 200353
Chlebowski et al, 200454
Cirillo et al, 200540
Cushman et al, 200455
Hays et al, 200356
Hendrix et al, 200357
Hendrix et al, 200542
Hsia et al, 200458
Manson et al, 200359
Manson et al, 201315
Margolis et al, 200460
Prentice et al, 200961
Rossouw et al, 20021
Rossouw et al, 200746
Tang et al, 201162
Toh et al, 201063
Wassertheil-Smoller et al,
200364
United States
Postmenopausal
Ages 50-79 y
3-mo washout period for women using hormone therapy
at baseline
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 8506)
Placebo (n = 8102)
Median duration, 5.6 y
Fair
WHI Estrogen + Progestin
postintervention and
postintervention extension
phases
Chlebowski et al, 200965
Chlebowski et al, 201047
Gramling et al, 200966
Heiss et al, 200867
Manson et al, 201315
15 747 participants from WHI (95%) had any
postintervention follow-up and 12 788 (77%) consented
to participate in the extension phase
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 8506)
Placebo (n = 8102)
Median duration, 8.2 y
Fair
Women’s Health Initiative
Memory Study
(WHIMS)—Estrogen
Espeland et al, 200468
Shumaker et al, 200469
United States
WHI participants enrolled in estrogen-only trial
Ages 65-79 y
Free of probable dementia
Able and willing to undergo annual cognitive assessment
CEE (0.625 mg/d) (n = 1464)
Placebo (n = 1483)
Duration, 5.2 y
Good
WHIMS—Estrogen + Progestin
Culhane, 200370
Rapp et al, 200371
Shumaker et al, 200372
United States
WHI participants enrolled in estrogen + progestin trial
Age >65 y
Free of probable dementia
Able and willing to undergo annual cognitive assessment
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 2229)
Placebo (n = 2303)
Duration, 5.4 y
Good
Women’s Health Initiative
Memory Study of Younger
Women (WHIMSY)
Espeland et al, 201373
United States
Postmenopausal
Ages 50-55 y
3-mo washout period for women using hormone therapy
at baseline
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 696)
Placebo (n = 630)
Duration, 7.2 y
Fair
Women’s Health Initiative Study
of Cognitive Aging
(WHISCA)—Estrogen
Espeland et al, 201074
Resnick et al, 200975
United States
WHIMS estrogen-only trial participants
Free of probable dementia
At 1 of 14 WHIMS centers
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 434)
Placebo (n = 452)
Duration, 2.7 y
Good
WHISCA—Estrogen + Progestin
Espeland et al, 201074
Resnick et al, 200676
United States
WHIMS estrogen + progestin trial participants
Free of probable dementia
At 1 of 14 WHIMS centers
CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 690)
Placebo (n = 726)
Duration, 3 y
Good
Women’s International Study of
Long Duration Estrogen After
Menopause (WISDOM)
Vickers et al, 200719
United Kingdom
Postmenopausal
Ages 50–69 y
CEE (0.625 mg/d) + MPA (2.5-5.0 mg/d) (n = 2196)
Placebo (n = 2189)
Duration, 1 y
Fair
Abbreviations: CEE, conjugated equine estrogen; MP, cyclic micronized
progesterone; MPA, medroxyprogesterone acetate; USPSTF, US Preventive
Services Task Force.
a Duration of follow-up and duration of active treatment (except for the
Women’s Health Initiative follow-up study, for which “duration” indicates
follow-up only).
b The quality of each study was assessed as good, fair, or poor using USPSTF
predefined criteria.12 Individual study quality ratings by domain are reported in
eTable 2 in the Supplement.
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pooled because of heterogeneity in study duration and outcome
measures. During the intervention phase of the WHI, women as-
signed to estrogen plus progestin had a statistically significant in-
crease in riskof invasivebreastcancer (9morecasesper 10000per-
son-years [95% CI, 1 to 19]).15 The risk of invasive breast cancer
remained significantly increased during amedian postintervention
follow-up of 8.2 years (HR, 1.32 [95%CI, 1.08-1.61]). The HERS trial
also reported that more women randomized to estrogen plus pro-
gestindevelopedbreast cancerduring the4.1-year (mean) interven-
tion phase than did the women receiving placebo, but the results
werenotstatistically significant (HR, 1.38[95%CI,0.82-2.31]).80The
other trials reported inconclusive findings.
Ameta-analysis of 3 trials (EPHT,20 PEPI,29 and theWHI1) with
data on 18 081 women yielded a numerically higher risk of coro-
nary events in women treated with combination therapy than in
those receiving placebo (8 more cases per 10 000 patient-years
[95% CI, 0 to 18]) (eFigure 2 in the Supplement).
One WHI trial (WHI Memory Study [WHIMS]72) evaluated the
risk of probable dementia or mild cognitive impairment among
4532 women taking estrogen plus progestin during 5.4 years of
follow-up. WHIMS was limited to women aged 65 to 79 years
at baseline who were free of probable dementia. Women using
estrogenplusprogestinhadahigher riskofprobabledementia than
those receiving placebo (22 more cases per 10000 patient-years
[95%CI, 4 to 53]).WHIMSdid not find an elevated risk ofmild cog-
nitive impairment.72
Based on the WHI data, risks for gallbladder disease (21 more
cases per 10000patient-years [95%CI, 10 to 34]), stroke (9more
cases per 10000 patient-years [95% CI, 2 to 19]), urinary inconti-
nence (876more cases per 10000 patient-years [95% CI, 606 to
1168]), and venous thromboembolism (21 more cases per 10000
patient-years [95%CI, 12 to 33]) were also statistically significantly
increased among women taking estrogen plus progestin com-
pared with women taking placebo (Figure 3). Because of small
sample sizes, other trials produced inconclusive results with wide
confidence intervals encompassing beneficial and harmful effects
on these outcomes.
The WHI global index balancing benefits and harms was asso-
ciatedwith 20 additional adverse events per 10000 person-years
for estrogen plus progestin therapy (HR, 1.12 [95%CI, 1.02-1.24]).15
Difference in Benefits and Harms by Subgroup
Key Question 3. Do the benefits and harms of menopausal hor-
monetherapydifferbysubgroup(raceorethnicity;womenwithpre-
mature menopause; women with surgical menopause; age during
hormone therapy use; duration of use; type, dose, andmodeof de-
livery of hormone therapy; and comborbid condition) or by timing
of intervention (initiation of hormone therapy during perimeno-
pause vs postmenopause)?
Subgroups
Trials did not report results for most of the subgroups. Subgroup
analyses were restricted to age, race/ethnicity, and a limited num-
ber of comorbidities or risk factors. In general, tests of interactions
didnotdetect any statistically significant subgroupeffects formost
outcomesof interest.Anexception is the interactionwithage.Analy-
ses that compared younger (50 to 59 years) with older (70 to 79
years)womenusing estrogen-only therapy yielded statistically sig-
nificant trends for increasing risks by age for myocardial infarction
(HR,0.55 [95%CI,0.31-1.00]vsHR, 1.24[95%CI,0.88-1.75];P = .02
for trend),15 colorectal cancer (HR, 0.71 [95% CI, 0.30-1.67] vs HR,
2.24 [95%CI, 1.16-4.30]; P = .02 for trend),15 and all-causemortal-
ity (HR, 0.70 [95% CI, 0.46-1.09] vs HR, 1.21 [95% CI, 0.95-1.56];
P = .04 for trend).15 Suchsubgroupdifferences, however, arebased
on relatively few events and should be interpreted cautiously. For
example, only48women in the50- to59-year-old agegroupexpe-
rienced a myocardial infarction. eTable 19 in the Supplement pre-
sents the strength of evidence for subgroup results.
Timing of Intervention
Post hoc subgroup analyses of WHI data regarding the association
of timingofhormone therapy (ie, initiationduringearly or latepost-
menopause) with benefits and risks found that time since meno-
pausedidnothavea statistically significant associationwith the risk
of coronary heart disease inwomenusing estrogen-only therapy.61
For combination therapy,oneposthocsubgroupanalysis found
that womenwho began therapywithin 10 years ofmenopause did
not have the elevated risk for myocardial infarction, unlike women
whostarted therapymore than20years aftermenopause (HR,0.91
[95%CI,0.54-1.52] vsHR, 1.99 [95%CI, 1.32-3.02];P = .01).15How-
ever, anotherposthocsubgroupanalysis tookhormone therapyuse
of women before enrollment into the WHI into consideration and
reported that coronary risks did not differ between early and late
initiation of hormone therapy.61
For several outcomes, no statistically significant differences
were found between women using hormone therapy and women
receiving placebo. For estrogen-only therapy, no statistically sig-
nificant differences were found for probable dementia, breast
Table 3. Estimated Event Rate Increase (Harm) or Decrease (Benefit)
per 10000 Person-Years AssociatedWith the Use of Hormone Therapy
Outcome
Event Rate Difference, per 10 000 Person-Years
(95% CI)
Estrogen Only Estrogen + Progestin
Breast cancer (invasive) −7 (−14 to 0.4) 9 (1 to 19)
Cervical cancer NAa 1 (−1 to 4)
Colorectal cancer 2 (−3 to 10) −6 (−9 to −1)
Endometrial cancer NAa −1 (−3 to 3)
Lung cancer 1 (−4 to 8) 1 (−4 to 7)
Ovarian cancer No data 2 (−1 to 6)b
Coronary heart disease −3 (−12 to 8) 8 (0 to 18)
Dementia (probable) 12 (−4 to 41) 22 (4 to 53)
Diabetes −19 (−34 to −3)b −14 (−24 to −3)b
Fractures (osteoporotic) −53 (−69 to −39)b −44 (−71 to −13)
Gallbladder disease 30 (16 to 48)b 21 (10 to 34)b
Stroke 11 (2 to 23) 9 (2 to 19)
Urinary incontinence 1261 (880 to 1689) 876 (606 to 1168)
Venous thromboembolism
(DVT or PE)
11 (3 to 22) 21 (12 to 33)
All-cause mortality 1 (−10 to 14) 1 (−9 to 12)
Abbreviations: DVT, deep vein thrombosis; NA, not applicable; PE, pulmonary
embolism.
a Not applicable to women after hysterectomy.
bPoint estimate is slightly different from estimate reported in Manson et al15
because of the use of relative risks instead of hazard ratios.
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cancer, colorectal cancer, lung cancer, coronary heart disease,
quality of life, and all-cause mortality. For estrogen plus progestin
therapy, no statistically significant differences were found for cer-
vical cancer, endometrial cancer, lung cancer, ovarian cancer,
quality of life, and all-causemortality. eTable 19 in the Supplement
presents the strength of evidence of these findings.
Discussion
Table 4 and Table 5 present summaries of the evidence for this
review. Women taking hormone therapy to prevent chronic condi-
tionsmay experience some benefits (eg, reduced risks for fractures
and diabetes) but also several important harms (eg, higher risks for
stroke, thromboembolic events, gallbladder disease, and urinary
incontinence). The WHI global index that balanced benefits and
harms of hormone therapy found no significant difference for
estrogen-only therapy but found significantly more harmful events
for combination therapy. These results pertain to asymptomatic
women who use hormone therapy for the purpose of preventing
chronic conditions. A recently published long-term follow-up study
of the WHI trials, however, showed that the exposure to hormone
therapy during the WHI intervention phases (5.6 years for
estrogen-only therapy and 7.2 years for estrogen plus progestin)
Figure 3. Absolute Risk Reductions or Increases forWomen TreatedWith Estrogen Alone andWith Estrogen Plus Progestin
–600 0 600 1200 1800
Absolute Risk Difference (95% CI),
Events per 10 000 Women
Estrogen aloneA
Benefits of
Hormone
Therapy
Harms of
Hormone
Therapy
No. of
Trials
Strength of
Evidence
No. of Events/Total No.
Treatment PlaceboOutcome
RR
(95% CI)
Absolute Risk
Difference, Events
per 10 000 Women
(95% CI)
Absolute Risk
Difference, Events
per 10 000 Women
(95% CI)
113 Moderate 104/5310 135/5429Breast cancer (invasive) –52 (–97 to 3)0.79 (0.61-1.01)
113 Low 65/5310 58/5429Colorectal cancer 1.15 (0.81-1.63) 16 (–20 to 73)
113 Low 62/5310 61/5429Lung cancer 1.04 (0.73-1.48) 5 (–30 to 54)
323,29,31 High 203/5596 224/5714Coronary heart disease 0.95 (0.79-1.14) –20 (–82 to 55)
177 Low 28/1464 19/1483Dementia (probable) 1.49 (0.84-2.66) 63 (–21 to 213)
113 Moderate 449/4900 527/5017Diabetes 0.87 (0.77-0.98) –137 (–242 to –21)
113 High 544/5310 767/5429Fractures (osteoporotic) 0.73 (0.65-0.80) –382 (–495 to –283)
139 Moderate 228/4141 143/4235Gallbladder disease 1.63 (1.33-2.00) 213 (111 to 338)
113 Moderate 169/5310 129/5429Stroke 1.33 (1.06-1.67) 79 (14 to 160)
141 Moderate 557/1526 368/1547Urinary incontinence 1.53 (1.37-1.71) 1261 (880 to 1689)
113 Moderate 137/5310 98/5429Venous thromboembolism 1.43 (1.11-1.85) 78 (20 to 153)
3 23,29,31 High 340/5923 342/6038All-cause mortality 1.01 (0.88-1.17) 6 (–74 to 96)
–600 0 600 1200 1800
Absolute Risk Difference (95% CI),
Events per 10 000 Women
Estrogen + progestinB
Benefits of
Hormone
Therapy
Harms of
Hormone
Therapy
No. of
Trials
Strength of
Evidence
No. of Events/Total No.
Treatment PlaceboOutcome
RR
(95% CI)
113 High 206/8506 155/8102Breast cancer (invasive) 1.27 (1.03-1.56) 52 (6 to 107)
165 Low 8/8506 5/8102Cervical cancer 1.52 (0.50-4.66) 3 (–3 to 23)
113 Moderate 50/8506 75/8102Colorectal cancer 0.64 (0.44-0.91) –33 (–52 to –8)
113 Low 27/8506 30/8102Endometrial cancer 0.86 (0.51-1.44) –5 (–18 to 6)
113 Moderate 78/8506 70/8102Lung cancer 1.06 (0.77-1.46) 5 (–20 to 40)
113 Low 24/8506 16/8102Ovarian cancer 1.43 (0.76-2.69) 9 (–5 to 33)
318,32,71 High 205/9506 155/8712Coronary heart disease 1.23 (1.00-1.52) 41 (7 to 93)
145 Moderate 40/2229 21/2303Dementia (probable) 1.97 (1.16-3.33) 88 (15 to 213)
137 Moderate 328/8132 373/7742Diabetes 0.84 (0.72-0.97) –77 (–135 to –15)
516,18,31,34,35 High 903/10 464 1092/10 035Fractures (osteoporotic) 0.80 (0.68-0.94) –221 (–353 to –66)
139 Moderate 228/7308 135/6895Gallbladder disease 1.59 (1.29-1.97) 116 (57 to 190)
141 Moderate 834/2675 563/2507Urinary incontinence 1.39 (1.27-1.52) 876 (606 to 1168)
113 Moderate 209/8506 102/8102Venous thromboembolism 1.95 (1.54-2.47) 120 (68 to 185)
331, 34, 35 Moderate 384/9990 368/9590All-cause mortality 1.01 (0.88-1.17) 4 (–48 to 68)
113 High 159/8506 109/8102Stroke 1.39 (1.09-1.77) 53 (12 to 104)
A, Follow-up periods for all outcomes are 7.1 years except for fractures
(7.2 years), probable dementia (5.2 years), and urinary incontinence (1 year).
B, Follow-up periods for all outcomes are 5.6 years except for fractures
(5.0 years), coronary heart disease (5.1 years), probable dementia (4 years),
and urinary incontinence (1 year). Relative risks (RRs) were calculated to
determine absolute risk reductions and increases presented in this Figure
because it is unclear whether the proportional hazards assumption is always
met in trials of long-term hormone therapy. Estimates of RRsmight differ
from hazard ratios of trials presented in the text. Estimates using 1 trial are
based on the best available single study. The quality of each study was assessed
as good, fair, or poor using USPSTF predefined criteria.12 Individual study quality
ratings by domain are provided in eTable 2 in the Supplement.
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was not associated with increased or decreased risks of all-cause,
cardiovascular, or cancer mortality during a cumulative follow-up of
18 years.81
A major point of discussion in recent years has been whether
the overall net benefit of hormone therapy usemay be increased if
therapy is started early during menopause transition or early post-
menopause. This approach is often referred to as the timing
hypothesis (ie, a critical window for favorable outcomes of hor-
mone therapy treatment).3 The hypothesis proposes that hor-
mone therapy given at or soon after menopause reduces the risks
of cardiovascular disease,4 mortality,6 and dementia,5 but the
potential beneficial effects will be attenuated or not experienced
when hormone therapy is initiated several years after menopause.
Current evidence on the effect of timing of initiation, however,
is inconclusive.
A recent Cochrane review assessed the timing hypothesis by
stratifying trials in ameta-analysis according towhen anyhormone
therapywas started (the reviewdid not stratify between estrogen-
only and combination therapy).82 If this information was not avail-
able, the authors used the mean age of participants at baseline as
surrogates, which is a substantial limitation of that review. Results
provided some support of the timing hypothesis. All-causemortal-
ity was lower in the subgroup of studies in which treatment was
started within 10 years of menopause compared with studies in
which more than 10 years had elapsed (P = .01). Likewise, the risk
of coronary heart disease was lower in women who began hor-
mone therapyearly (P = .02).Nevertheless,becauseof issuesofpo-
tential ecological fallacy, findings of such study-level analyses have
to be viewed cautiously.
Another study sometimes viewedas supporting the timinghy-
pothesis is theDanishOsteoporosisPreventionStudy(DOPS).83That
studywasnotconsidered in themainsynthesisbecauseofpoorqual-
ity attributable to lack of blinding of outcomes assessors. In addi-
tion, its findings are limited by the small number of events and the
imprecision of the estimates. For example, during 10 years of treat-
ment, only 49 cardiovascular events took place.
Limitations
This review and the underlying evidence base have several limita-
tions. First, the trials were restricted to those published in English.
Because of the large number of included trials, however, we be-
lieve that inclusion of studies not published in English would not
affect our conclusions.
Second, most included trials had high attrition or low adher-
ence tomedications; this was true even for theWHI, inwhich 40%
to 50% of participants discontinued their medications during the
trial.Nevertheless, secondary analysesof theWHI limited toadher-
ent women (ie, censoring women within 6months of their report-
ing less than 80% adherence to study pills) were generally similar
to intention-to-treat results15 but with stronger findings.
Third, low event rates also limited conclusions for some out-
comes. For example, in theWHI Estrogen plus Progestin Trial, only
40womendevelopedovarian cancer. Likewise, event rates for cer-
vical and endometrial cancers were low, rendering wide confi-
dence intervals that encompassed clinically meaningful differ-
ences in risks. Thus, confidence in conclusions about benefits and
risks of hormone therapy for some outcomes (cervical, endome-
trial, and ovarian cancer) is low.Ta
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Fourth, themajority of women (around 80%)were white. Sub-
groupanalysesdidnotdid identifydifferences inbeneficialorharmful
effectsamongethnicgroups,butsuchanalyseswere likelyunderpow-
ered. Moreover, the majority of findings came from the WHI, which
testedonly1dose,formulation,androuteofadministrationofhormone
therapyineachtrial(oralconjugatedequineestrogen[0.625mg/d]with
orwithoutmedroxyprogesterone[2.5mg/d]).Whetherdifferent for-
mulationshavedifferent risk-benefit profiles remains unclear.
Conclusions
Hormone therapy for the primary prevention of chronic conditions
inmenopausalwomen isassociatedwithsomebeneficial effectsbut
alsowith a substantial increase of risks for harms. The available evi-
dence regarding benefits and harms of early initiation of hormone
therapy is inconclusive.
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